News & Events
Published On: 3/17/2020
TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
Real-world clinical data company, TARGET PharmaSolutions Inc., announced today new partnerships with two multinational pharmaceutical corporations to support the TARGET-DERM observational study. They join current partner Novartis in support of this collaboration to evaluate adult and pediatric patients with atopic dermatitis (eczema) and other immune-mediated inflammatory skin conditions.
“The two new collaborative industry partnerships are evidence that TARGET’s real-world data is extremely valuable to the dermatology community,” said TARGET PharmaSolutions CEO, Neal Bibeau. “These companies join TARGET in our commitment to improving patient lives, and we are thrilled to play a key role in helping to inform their future direction with a base of strong scientific evidence.”
TARGET’s real-world database enrolls consented patients across a variety of community and academic sites to collect the structured and unstructured medical record data needed to inform optimal and individual treatment approaches. The real-world data can be utilized throughout the pharmaceutical development and commercialization process.
“The longitudinal, real-world data that TARGET-DERM is collecting will help to shape understanding of the natural history of atopic dermatitis,” said TARGET-DERM Steering Committee Co-Chair, Emma Guttman-Yassky, MD, PhD, professor and vice chair for research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai Medical Center. “It will also capture important treatment safety and effectiveness of new agents across populations as they come to market.”
Launched in 2019, TARGET-DERM is the sixth disease community created by TARGET since 2015. The first disease community launched by the company, TARGET-NASH, is currently in its fourth year of data collection. Other ongoing TARGET studies include hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV). TARGET-ASTHMA is the newest community developed.
To create each real-world community, the TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis on the disease’s natural history, current treatment paradigms, and patient outcomes. This includes key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who are responsible in answering strategic questions and determining the study’s structure.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
01/15/2021Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
12/21/2020TARGET-HCC Initial Manuscript Published in Hepatology Communications
12/18/2020Target RWE Virtual Posters at Annual AIBD, RAD Conferences
11/28/2020TARGET-DERM Objectives Published in BMJ Open
11/13/2020Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities